🏛️ Verified NIH Record • Updated 2026-05-01

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (NCT06311721)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Amgen

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (Keytruda®).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (6 items).

Location: Precision NextGen Oncology and Research Center — Beverly Hills, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Small cell lung cancer (SCLC) or mixed SCLC/NSCLC histology or squamous cell carcinoma.
  • Participant has active central nervous system metastases not previously treated.
  • Participant has active or known immune-mediated disorders.
  • Participant has received prior systemic cytotoxic chemotherapy, immunotherapy (including PD-1/PD-L1), anti-neoplastic biological therapy, or targeted therapy for advanced/metastatic disease.
  • Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug, or to any component of cisplatin, carboplatin, or pemetrexed.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (218 Sites)

  • Precision NextGen Oncology and Research Center — Beverly Hills, California
  • TOI Clinical Research — Cerritos, California
  • Cancer and Blood Specialty Clinic (CBSC) — Los Alamitos, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • PIH Health Hospital — Whittier, California
  • Millennium Oncology - Hollywood — Hollywood, Florida
  • BRCR Medical Center Inc. — Tamarac, Florida
  • Accellacare Duly — Plainfield, Illinois
  • Accellacare of McFarland — Ames, Iowa
  • Detroit Clinical Research Center, PC — Farmington Hills, Michigan
  • North Shore Hematology-Oncology Associates P.C. d/b/a New York Cancer & Blood Specialists — Shirley, New York
  • Gabrail Cancer Center Research — Canton, Ohio
  • Millennium Research and Clinical Development, LLC — Houston, Texas
  • Texas Oncology, P.A — San Antonio, Texas
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Wytheville, Virginia
  • Instituto de Investigaciones Clinicas Mar del Plata — Mar del Plata, Buenos Aires
  • Centro de Investigacion Pergamino SA — Pergamino, Buenos Aires
  • Fundacion ARS Medica — San Salvador de Jujuy, Jujuy Province
  • Sanatorio Britanico De Rosario — Rosario, Santa Fe Province
  • Hospital Provincial del Centenario — Rosario, Santa Fe Province
  • IONC - Instituto Oncologico de Cordoba — Córdoba,
  • Klinikum Klagenfurt am Woerthersee — Klagenfurt,
  • Ordensklinikum Linz GmbH Elisabethinen — Linz,
  • CRIO - Centro Regional Integrado de Oncologia — Fortaleza, Ceará
  • OC Oncoclinicas Oncovida — Brasília, Destrito Federal

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗